Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Clascoterone and RU-58841 Interaction: Monitor | Peptide Database

Compound Profiles Clascoterone Topical Androgen Receptor Inhibitor | Acne & Hair Loss Clascoterone acts as a competitive antagonist of the androgen receptor (AR). When applied topically, it penetrates the skin and binds directly to androgen receptors in target

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Compound Profiles

Clascoterone

Topical Androgen Receptor Inhibitor | Acne & Hair Loss

Clascoterone acts as a competitive antagonist of the androgen receptor (AR). When applied topically, it penetrates the skin and binds directly to androgen receptors in target tissues -- sebaceous glands (for acne) and dermal papilla cells of hair follicles (for alopecia).

RU-58841

Topical Anti-Androgen | Experimental Hair Loss Treatment

RU-58841 functions as a competitive antagonist of the androgen receptor (AR). When applied topically to the scalp, it penetrates the skin and binds directly to androgen receptors in dermal papilla cells of hair follicles, preventing dihydrotestosterone (DHT) and testosterone from activating those receptors.

Combined Organ Load

Shared Safety Flags

Frequently Asked Questions

Can I take Clascoterone with RU-58841?

Yes, but with caution. Both clascoterone and RU-58841 are androgen receptor antagonists applied topically to block DHT at the follicle. Using both simultaneously provides overlapping rather than complementary mechanisms and could increase the risk of local irritation or, theoretically, additive anti-androgenic effects if absorption occurs. There is no clinical rationale for combining two topical AR antagonists; one or the other is recommended. Regular monitoring is advised.

Is Clascoterone and RU-58841 safe together?

Based on documented research, this combination is considered monitor. However, shared safety flags include: teratogenic. Monitor accordingly.

What are the interactions between Clascoterone and RU-58841?

Both clascoterone and RU-58841 are androgen receptor antagonists applied topically to block DHT at the follicle. Using both simultaneously provides overlapping rather than complementary mechanisms and could increase the risk of local irritation or, theoretically, additive anti-androgenic effects if absorption occurs. There is no clinical rationale for combining two topical AR antagonists; one or the other is recommended. This assessment has 90% confidence and is based on documented research data.

How should I time Clascoterone and RU-58841?

Clascoterone has a half-life of Short topical (local action; rapidly metabolized to cortexolone) and RU-58841 has a half-life of ~1 hour topically (very short systemic half-life). No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

This interaction analysis is compiled from research literature and pharmacological mechanism data. Always consult a healthcare professional before combining compounds.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

comparison

What's the ideal 5/5 vs 10/3 ratio for Tesa/IPA and when to use each?

5/5 (equal parts) provides balanced GH stimulation suitable for general recovery. The 10/3 (higher tesamorelin) variant emphasizes visceral fat loss and metabolic effects. Choose 5/5 for at…

Source: peptide-db.com
comparison

BPC-157 vs TB-500: Mechanisms, Dosing & the Wolverine Stack

How BPC-157 and TB-500 compare for healing: mechanism differences, dosing protocols, clinical evidence, and when to combine both in the Wolverine Stack.

Source: peptide-db.com
comparison

What's the addiction risk of phenibut vs benzodiazepines?

Phenibut carries similar addiction and withdrawal risk to benzodiazepines despite not being a benzo. Physical dependence can develop in as little as 1-2 weeks of daily use, and withdrawal i…

Source: peptide-db.com
Research context

Read sources and limitations before applying a claim.

Community Research

Join others researching Ketoconazole — share findings, ask questions, and learn from real experiences Ketoconazole is an FDA-approved azole antifungal that has gained widespread use as a topical adjunct in hair loss treatment. Available as a 1-2% medicated shampoo, ketoconazole disrupts DHT binding at the hair follicle and reduces scalp inflammation driven by the fungus Malassezia, both of which contribute to follicular miniaturization. It is a core component of the widely referenced "big 3" hair loss stack alongside finasteride and minoxidil. While ketoconazole was originally developed as a systemic antifungal for conditions like fungal infections and seborrheic dermatitis, its topical anti-androgenic properties at the scalp level have made it a practical and low-risk addition to hair loss regimens. When used as a shampoo, systemic absorption is negligible, keeping the side effect profile limited to occasional local irritation. Ketoconazole works through multiple pathways relevant to hair loss. As an azole antifungal, it inhibits the enzyme lanosterol 14-alpha-demethylase, disrupting ergosterol synthesis and killing Malassezia fungi that colonize the scalp and contribute to inflammation and seborrheic dermatitis. This anti-inflammatory effect reduces the chronic follicular inflammation associated with androgenetic alopecia. Independently, ketoconazole has demonstrated topical anti-androgenic activity by disrupting the binding of dihydrotestosterone (DHT) and other androgens to receptors at the hair follicle. Some evidence also suggests it may interfere with local androgen synthesis pathways. Unlike systemic anti-androgens such as finasteride, ketoconazole shampoo exerts these effects locally at the scalp without meaningful systemic hormonal changes, making it a well-tolerated complement to oral DHT-blocking therapies.

Source: peptide-db.com ↗

Research Indications

Primary mechanism activating dormant muscle satellite cells which fuse to damaged fibers. Increases proliferative lifespan in younger muscle progenitor cells. Increases activated satellite cell fusion capacity supporting repair and hypertrophy. Animal studies suggest improved Achilles tendon injury outcomes. Rabbit models demonstrated faster healing via osteoblast regulation. Research indicates potential for articular cartilage injury models. Naturally upregulated after mechanical stress; supplementation may enhance processes. Localized injection near injury sites supports targeted tissue repair.

Source: peptide-db.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

Dosage reference

Dosing Protocols

RAD-140 is administered exclusively via the oral route. It is available as a liquid solution (typically dissolved in a carrier such as PEG-400 or ethanol) or in capsule form from research chemical suppliers. The compound has high oral bioavailability due to its nonsteroidal structure and resistance to first-pass metabolism. Its long half-life of approximately 60 hours allows for once-daily dosing with stable plasma concentrations achieved within 1-2 weeks. Research Dose - Conservative 10 mg/day Once daily Oral (liquid or capsule) Research Dose - Moderate 15-20 mg/day Research Dose - Upper Range 20-30 mg/day

Source: peptide-db.com ↗
Side effects

Common Side Effects

Generally well-tolerated in research Possible mild increase in body temperature (less than DNP)

Source: peptide-db.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →

Continue learning

Related guides